Current and historical daily PE Ratio for Adynxx Inc (
FRA:HL1C
) from 1998 to Jun 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Adynxx stock (FRA:HL1C) PE ratio as of Jun 25 2024 is 0.
More Details
Adynxx Inc (FRA:HL1C) PE Ratio (TTM) Chart
Adynxx Inc (FRA:HL1C) PE Ratio (TTM) Historical Data
View and export this data going back to 1998. Start your Free Trial
Total 0
- 1
| Adynxx PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
Adynxx Inc (FRA:HL1C) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Adynxx Inc
NAICS : 325412
SIC : 2899
ISIN : US0196213096
Description
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers